Immuno Monitoring in Patient With Epithelial Ovarian Cancer Eligible to PARP Inhibitors (IMMUNOPARP)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Jean-David FUMET
- Phone Number: 03 80 73 75 00
- Email: jdfumet@cgfl.fr
Study Locations
-
-
-
Besançon, France, 25000
- CHRU Jean Minjoz
-
Dijon, France, 21000
- Centre Georges François Leclerc
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
- Cohort 1: Maintenance treatment of adult patients with newly diagnosed BRCA1/2-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer (FIGO stages III and IV) who have had a partial or complete response to first-line platinum-based chemotherapy. BRCA-mutated epithelial ovarian cancer - maintenance with Olaparib / Niraparib or Olaparib + bevacizumab
- Cohort 2: Single-agent maintenance treatment of adult patients with platinum-sensitive, recurrent primary epithelial ovarian, fallopian tube or peritoneal cancer who are responding (complete or partial) to platinum-based chemotherapy. Recurrent epithelial ovarian cancer - maintenance with Niraparib or Olaparib
Description
Inclusion Criteria:
- Patient over 18 years
- Patient treated for epithelial ovarian cancer
Eligible for anti-PARP therapy and in one of the 2 cohorts below:
- Cohort 1: Maintenance treatment of adult patients with newly diagnosed advanced epithelial ovarian, fallopian tube or primary peritoneal cancer (FIGO stages III and IV) with or without BRCA1/2 mutation, who have had a partial or complete response to first-line platinum-based chemotherapy.
- 2nd cohort: single-agent maintenance treatment of adult patients with platinum-sensitive, recurrent primary epithelial ovarian, fallopian tube or peritoneal cancer who have responded (completely or partially) to platinum-based chemotherapy.
- Patient having signed the informed consent form.
- Patient fit and able to comply with the protocol for the duration of the study, including visits, scheduled sampling and follow-up.
- Patient affiliated to the social security system.
Exclusion Criteria:
- Non-epithelial tumour of the ovary
- Patient unable to understand, read and/or sign informed consent.
- Current or previous use of immunosuppressive medication within 14 days prior to inclusion (except intranasal corticosteroids, systemic corticosteroids in physiological doses not exceeding 10 mg daily of prednisone or its equivalent, corticosteroids used as premedication for hypersensitivity reactions.
- Patient participating in other research that may modify the systemic treatment administered in the cohort in which she will be included.
- Pregnant or breast-feeding women.
- HIV and/or HBV and/or HCV serology positive.
- Patient refusal.
- Person benefiting from a system of protection for adults (including guardianship, curatorship and safeguard of justice).
- Inability to undergo medical follow-up for geographical, social or psychological reasons.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
First-line epithelial ovarian cancer (30 patients)
Maintenance treatment of adult patients with newly diagnosed advanced epithelial ovarian, fallopian tube or primary peritoneal cancer (FIGO stages III and IV) with or without BRCA1/2 mutation who have had a partial or complete response to first-line platinum-based chemotherapy.
|
Blood sampling during PARP inhibitor therapy
|
|
Recurrent epithelial ovarian cancer (20 patients)
Single-agent maintenance treatment of adult patients with primary, recurrent, platinum-sensitive epithelial ovarian, fallopian tube or peritoneal cancer who have responded (completely or partially) to platinum-based chemotherapy.
|
Blood sampling during PARP inhibitor therapy
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Immune response in plasma
Time Frame: From date of inclusion until the date of first documented progression or date of death from any cause assessed up to 24 months
|
Realization of a plasma library
|
From date of inclusion until the date of first documented progression or date of death from any cause assessed up to 24 months
|
|
Immune response in PBMC
Time Frame: From date of inclusion until the date of first documented progression or date of death from any cause assessed up to 24 months
|
Realization of a PBMC bank
|
From date of inclusion until the date of first documented progression or date of death from any cause assessed up to 24 months
|
|
Immune response in tumor DNA
Time Frame: From date of inclusion until the date of first documented progression or date of death from any cause assessed up to 24 months
|
Realization of a circulating tumor DNA bank
|
From date of inclusion until the date of first documented progression or date of death from any cause assessed up to 24 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Genital Neoplasms, Female
- Endocrine System Diseases
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Ovarian Neoplasms
- Carcinoma, Ovarian Epithelial
Other Study ID Numbers
Other Study ID Numbers
- 2020-A00036-33
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.